Search Result for : Generic Medicines

The Dollar Business Bureau A leading Indian pharmaceuticals company Aurobindo Pharma has said that it would widen its product portfolio in the American market while planning to enter new markets in the Europe, a part of the company’s growth strategy in the coming 3-4 years. In the US market, Aurobindo Pharma plans to widen its portfolio through faster growth in OTC, injectable and higher complexity products, the company said in a presentation to investors. However, in European market, the company plans to enhance its presence in new geographies like Czech Republic and Poland, in addition to strengthening its position in the existing markets of Germany, France, Spain, Netherlands and the UK. Aurobindo Pharma is the 6th largest generic company by volume in the US, ...

The Dollar Business Bureau World Trade Organisation (WTO) has finalised a deal that allows poor countries, which do not have manufacturing infrastructure for the production of generic drugs, to import the same. The proposal has been awaiting approval since 2005. It finally got ratified by two-thirds majority on 23 January, 2017. "The amendment to the Trade Related Aspects of Intellectual Property (TRIPS) agreement gives the world's most vulnerable people access to drugs for diseases such as HIV/AIDS, tuberculosis and malaria," WTO Director General Roberto Azevedo said. Countries are permitted to produce generic versions of patented drugs for their domestic markets since the beginning of WTO regime in 1995. Only in 2003 were the poor countries given a temporary waiver to import these drugs. Ever since, it has been renewed every two years until ...

The Dollar Business Bureau What is said to be the biggest investment by an Indian pharmaceutical major in Europe following the Brexit outcome, Ahmedabad-based Intas has acquired Actavis Generics in the United Kingdom and Ireland for £600 million (around Rs.5100 crore) from Israel's Teva in an all-cash deal. A part of the European Commission's anti-trust divestiture needs emerging from Teva acquisition of Actavis Generics from Ireland-based Allergan unit for $40 billion, the transaction would enable the Indian drug major to tap a high-potential and always-growing UK and Ireland generics markets. This deal will prompt the company to undertake expansion-related initiatives, and it is expected that the company will add one more manufacturing capability to its existing three plants in the UK, ...

Aadhira Anandh   The 4th edition of Pharma Pro &Pack Expo 2016, an international exhibition for Pharma’s technology and trade was unveiled on 27th April in Mumbai. The event is being organized by India Pharma Machinery Manufacturers Association (IPMMA) and GPE Exports Pvt. Ltd. Hosted in association with the EEPC India and PHARMEXCIL, the expo largely concentrates on the Indian Pharma engineering and the Indian Pharmaceutical Industry. The expo provided a common platform for trade opportunities to MSME’s on both national and international levels.  Simultaneously in another part of the exhibition ground Pharma Lab Expo 2016, an international exhibition of total pharma manufacturing technologies was organized. It focused on providing the experience of new technologies to the pharma buyers and sellers in the industry.  The ...

 The Dollar Business Bureau Aurobindo Pharma, a Hyderabad-based company, has announced that it has finally received approval to manufacture and market Oxymorphone Hydrochloride and Famotidine tablets from the United States Food and Drug Administration (USFDA). The approved Abbreviated New Drug Application (ANDA) is bio and therapeutic equivalent to listed drug under Reference Listed Drug (RLD). Manufactured by Endo Pharmaceuticals, Inc., Oxymorphone Hydrochloride is a pain relief drug for moderate to acute pain, wherever the prescription of Opioid is appropriate. As approved by ANDA, dosages must be 5mg and 10mg. According to IMS Health, the product has a market size of $55.5 million for a period of 12-months, ending February 2016. While, Famotidine tablets (ANDA approved dosages for this drug is ...

The Dollar Business Bureau Lupin Ltd, a transnational pharmaceutical company developing an extensive range of generic and branded formulations, has launched Zolpidem Sublingual tablets - a generic drug prescribed for insomnia, in the American markets. The first product from its GAVIS pipeline, Zolpidem Sublingual Tablets is a generic equivalent of Purdue Pharma LP’s Intermezzo® Sublingual Tablets. Lupin, the sixth largest generic player in the US, launched the drug after receiving a final approval from the US Food & Drug Administration (FDA) and a final clearance from the FTC, with six months of marketing exclusivity. Intermezzo® Sublingual Tablets are indicated for treating insomnia, a sleep disorder where a person finds difficulty in falling and/or staying asleep. Earlier this month, in a $880 million deal, Lupin had ...

Union Minister of Chemicals and Fertilizers Ananth Kumar announced the setting up of the first medical device industry park in Gujarat The Dollar Business Bureau The Union Minister for Chemicals and Fertilizers Ananth Kumar at the India Medical Expo-2016 in Bengaluru on Thursday.   The India Pharma Expo being held in Bangalore is aimed at increasing overall growth of the pharmaceutical sector including exports and focuses on increasing domestic production. The three-day international exhibition and conference also strives to encourage Make in India for manufacturing drugs and pharma machines and also provides a platform to global investment community to connect with stakeholders. Speaking at inaugural session of the conference, Minister of Chemicals and Fertilizers Ananth Kumar said that the government is working on removing bottlenecks ...

Source: PTI Germany's drug regulator has suspended the marketing of 54 medicines clinically tested by India's pharmaceuticals research company GVK Biosciences in compliance with the European Union's ban on around 700 generic drugs. The Federal Institute for Medicines and Medical Products (BfArM) in Bonn said on Friday that it published a new list of medicines taken out of the supply chain in this country on the basis of the largest EU-wide suspension of sales and distribution of generic medicines ordered by the European Commission last month. The commission's decision was in response to a recommendation by the EU drug regulator, the European Medicines Agency (EMA), in January, said that the marketing authorisation of these drugs should be suspended on the grounds that ...